Vical (NASDAQ:VICL) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.
Valuation and Earnings
This table compares Vical and Allogene Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vical||$1.62 million||16.20||-$16.25 million||($0.81)||-1.42|
Insider and Institutional Ownership
33.8% of Vical shares are owned by institutional investors. Comparatively, 53.5% of Allogene Therapeutics shares are owned by institutional investors. 4.6% of Vical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Vical and Allogene Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Vical and Allogene Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vical presently has a consensus target price of $4.00, indicating a potential upside of 247.83%. Allogene Therapeutics has a consensus target price of $37.57, indicating a potential upside of 39.46%. Given Vical’s higher possible upside, equities analysts plainly believe Vical is more favorable than Allogene Therapeutics.
Allogene Therapeutics beats Vical on 6 of the 11 factors compared between the two stocks.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.